Exact Sciences (EXAS) Tops Q1 EPS by 9c, Offers FY Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. PLTR
6. JNJ
7. HUM
8. CSCO
9. KTOS
10. NVDA

Go back to Exact Sciences (EXAS) Tops Q1 EPS by 9c, Offers FY Guidance

Cologuard growth accelerates to $48.4 million in revenue during first quarter; volume grows 150 percent year over year to 100,000 completed tests

April 27, 2017 6:00 AM EDT

MADISON, Wis., April 27, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenues of $48.4 million and completed approximately 100,000 Cologuard tests during the quarter ended March 31, 2017. First-quarter 2017 revenues and completed Cologuard test volume grew 226 percent and 150 percent from the same period of 2016, respectively.

"Our team is proud of the impact we are having on the early detection of colon cancer," said Kevin Conroy, chairman and CEO of Exact Sciences. "More than 450,000 people have been... More